Paraoxonase1 polymorphism Leu-Met55 is associated with cerebral infarction in Japanese population

Medical Science Monitor

Volumn 9, Issue 6, 2003, Pages

  Ueno, Takahiro ^a   Shimazaki, Emi ^a   Matsumoto, Taro ^a   Watanabe, Hideyuki ^a   Tsunemi, Akiko ^a   Takahashi, Yumiko ^a   Mori, Mayumi ^a   Hamano, Rumi ^a   Fujioka, Takayuki ^a   Soma, Masayoshi ^a   Matsumoto, Koichi ^a   Kanmatsuse, Katsuo ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerebral infarction; Japanese; Paraoxonase 1; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; LEUCINE; METHIONINE;

ADULT; AGED; ALLELE; ARTICLE; ATHEROSCLEROSIS; BRAIN INFARCTION; CAUCASIAN; CONTROLLED STUDY; DIGESTION; ENZYME SPECIFICITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ARYLDIALKYLPHOSPHATASE; CEREBRAL INFARCTION; CHOLESTEROL; DIABETES MELLITUS; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; JAPAN; LEUCINE; LIPOPROTEINS; MALE; METHIONINE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; TRIGLYCERIDES;

EID: 0038168097     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gordon DJ, Probstfield JL, Garrison RJ et al: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989; 79: 8-15
2. Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis, 1995; 115: 243-53
3. Mackness MI, Arrol S, Mackness B, Durrington PN: Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet, 1997; 349: 851-2
4. Watson AD, Berliner JA, Hama SY et al: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest, 1995; 96: 2882-91
5. Kelso GJ, Stuart WD, Richter RJ et al: Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry, 1994; 33: 832-9
6. Li WF, Furlong CE, Costa LG: Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett, 1995; 76: 219-26
7. Pond AL, Chambers HW, Chambers JE: Organophosphate detoxication potential of various rat tissues via A-esterase and aliesterase activities. Toxicol Lett, 1995; 78: 245-52
8. Aviram M, Rosenblat M, Bisgaier CL et al: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Clin Invest, 1998; 101: 1581-90
9. Shih DM, Gu L, Xia YR et al: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 1998; 394: 284-7
10. Mackness B, Mackness MI, Arrol S et al. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett, 1998; 423: 57-60
11. Humbert R, Adler DA, Disteche CM et al: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet, 1993; 3: 73-6
12. Serrato M, Marian AJ: A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest, 1995; 96: 3005-8
13. Ruiz J, Blanche H, James RW et al: Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet, 1995; 346: 869-72
14. Sanghera DK, Saha N, Aston CF, Kamboh MI: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol, 1997; 17: 1067-73.
15. Zama T, Murata M, Matsubara Y et al: A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol, 1997; 17: 3565-9
16. Sanghera DK, Aston CE, Saha N, Kamboh MI: DNA polymorphisms in two paraoxonnase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet, 1998; 62: 36-44
17. Mackness B, Mackness MI, Arrol S, et al: Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis, 1998; 139: 341-9
18. Garin MC, James RW, Dussoix P et al: Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest, 1997; 99: 62-6
19. Ueno T, Tremblay J, Kunes J et al: Resolving the composite trait of hypertension into its pharmacogenetic determinants by acute pharmacological modulation of blood pressure regulatory systems. J Mol Med, 2003; 81: 51-60
20. Ombres D, Pannitteri G, Montali A et al: The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Arterioscler Thromb Vasc Biol, 1998; 18: 1611-6
21. Sanghera DK, Saha N, Kamboh MI: The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis, 1998; 136: 217-23
22. Schmidt H, Schmidt R, Niederkorn K et al: Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke, 1998; 29: 2043-8
23. Leus FR, Wittekoek ME, Prins J et al: Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis, 2000; 149: 371-7
24. Fortunato G, Rubba P, Panico S et al: A paraoxonase gene polymorphism, PON1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women. Atherosclerosis, 2003; 167: 141-8
25. Mackness B, Mackness MI, Arrol S et al: Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol, 1997; 122: 265-8
26. Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 1993; 104: 129-35
27. Mackness B, Hunt R, Durrington PN, Mackness MI: Increased immunolocalization of paraoxonase, dusterin, and apolipoprotein A-1 in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol, 1997; 17: 1233-8